January 27, 2021 -- Thermo Fisher Scientific has launched a new medium of the first human T lymphocytes (T cells) specifically designed for allogeneic cell therapy workflows.
The Gibco CTS OpTmizer Pro Serum Free Media (SFM) targets the metabolism of healthy donor cells, making it well-suited for use in the production of allogeneic, off-the-shelf cell therapies. The serum free media is compatible with automated and longer workflows and is suited for a closed system. SFM enhances donor T-cell proliferation, maintains central memory T cells further into expansion, and delays effector differentiation of healthy donor T cells, according to the company.